• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    METHOD OF OBTAINING 6 7-DICHLOR-1, 5-DIHYDROIMIDAZO
    公开号:SU1120923A3
    申请号:SU792751007
    申请日:1979-04-09
    公开日:1984-10-23
    发明作者:Эндрю Дженкс Томас；Нейл Биверунг Уоррен (Младший)；Энтони Партика Ричард
    申请人:Бристоль Мейерз Компани (Фирма)；
    IPC主号:
    专利说明:

    31
    A mixture containing hydrobromic ethid-5,6-dichloro-dihydro-2 (1H) -iminochinazolin-3-acetate 6 g (0.043 mol), absolute ethanol (2.8 ml and triethylamine 0.66 ml (0.004 mol), heated The mixture is cooled and removed by decantation of ethanol as possible. The solid is then suspended in freshly prepared absolute ethanol and, after stirring the mixture for 0.5 h, filtered. The solid is then suspended in a mixture of absolute ethanol ( 3.8 ml) and 95% ethanol (15 ml) and heated under reflux in t chenie 4 hours. The warm mixture was filtered. The solid suschat. under vacuum (0.5-1 mm Hg) over phosphorus pentoxide. A 1.45 g (92%) of product
    09234
    as a solid ivory.
    IR peaks: 1702 (weak), 1638, 1554, 1468 and 1440
    5 NMR peaks (TFA): S 7.33 (AB, q, .2H)
    4.97 (S, 2H) and 4.59 (S, 2H).
    The compounds of formula III have the same structural formula, however, the compound of formula III can exist 10 also in tautomeric form Ilia:
    N. ,, NH-HBr
    T. about
    N II
    dHgdodgHs
    Moreover, both tautomeric forms, i.e. 20 III and Ilia, when treated with a base, give the required product of formula 1.
    权利要求:
    Claims (2)
    [1]
    METHOD FOR PRODUCING 6,7-Dichloro-1,5-dihydroimidazo (2,1-b) quinazoline
    [2]
    2 (ZN) -0 ON FORMULAS,
    Cl comprising the interaction of a compound of the formula with bromine in .kn 2 z o 'CH 2 LNSN 2 С0С g Н5 organic solvent, characterized in that, in order to increase the yield of the target product, toluene and the resulting compound of the formula w NH- are used as an organic solvent HBr
    Υ θ
    L ΑΛΑ II
    Ct γ Sn 2 Cos 2 n 5
    Cl is reacted with an equimolar amount of an organic base, for example triethylamine, in ethanol while heating. to the reflux temperature of the solvent.
    SU ,,,, 1120923 t 1
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1120923A3|1984-10-23|Method of obtaining 6,7-dichloro-1,5-dihydroimidazo|quinazoline 2 |-on
    ES2201397T3|2004-03-16|PROCEDURE FOR THE PREPARATION OF SILIDENAFILO.
    US3669979A|1972-06-13|Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst
    US4353829A|1982-10-12|Process for 5-aroylation of 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic esters
    Ulrich et al.1968|Synthesis and reactions of" anhydrochloralurethanes"
    DE19857765A1|2000-06-21|Process for the preparation of para-oxadiazolyl-phenyl-boronic acids
    JPS5618983A|1981-02-23|Theophylline derivative and its preapration
    US4412075A|1983-10-25|Process for the preparation of quinolin-4-ones
    KR0172965B1|1999-02-01|Preparation of 5,7-dihydroxy-1,2,4-triazolo|-pyrimidine-2-sulfonanilide
    Chen et al.1977|Cycloaddition Reactions of transition metal-2-alkynyl complexes with diphenylketene, t-butylcyanoketene, N-sulfinylaniline, and N-Sulfinyl-p-toluenesulfonamide
    CH638517A5|1983-09-30|Process for preparing substituted aminoquinazoline derivatives
    RU2111960C1|1998-05-27|Method of synthesis of 1-amino-1-cyanamido-2,2-dicyanethylene sodium salt
    US4150027A|1979-04-17|Process for preparing 2-hydroxybenzothiazole compounds
    LaMattina et al.1988|Synthesis of 2-amino-5-hydroxy-4-pyrimidones and 5, 6-biheteroaryls using p-nitrophenyl 3-bromo-2, 2-diethoxypropionate |
    JPH07285920A|1995-10-31|New aminocarboxylic acid ester and its preparation
    EP0119091A2|1984-09-19|2,2-Diethoxypropionic acid derivatives
    US4013674A|1977-03-22|N-|-formimide-chloride for synthesizing trichlorothiazole
    SU1447825A1|1988-12-30|Method of producing 3a-7a=diphenyltetrahydroimidazo/4,5-d/-imidazol-2,5-dion
    US4255335A|1981-03-10|Preparation of 5-aroyl-1-loweralkylpyrrole-2-acetic acid derivatives
    FI71931B|1986-11-28|LAEGRE ALKYL-5,6-DICHLORO-3,4-DIHYDRO-2 | -IMINOQUINAZOLINE-3-ACETATEHYDROHALOGENIDER THERE IS AN ANALYZING OF BUTTER PRODUCTS WITH FRAMSTATION OF THERAPEUTIC VAERDEFULL 6,7-DICHLORO1,5-DICHLORO1,5 B / KINAZOLIN-2 | -ON OCH FOERFARANDE FOER DEAS FRAMSTAELLNING
    US3862154A|1975-01-21|4-chloro-7-|-3-quinolinecarboxylates
    US4668831A|1987-05-26|Tert-Butyl-halophenols
    TAKIZAWA1952|Synthesis of Amino Acids using Liquid Ammonia. II
    US3642776A|1972-02-15|1-formyl-2-halogeno-azacycloalkenes and process for their production
    KR790001741B1|1979-12-16|Process for the praparation of bezoic amides
    同族专利:
    公开号 | 公开日
    DK156062B|1989-06-19|
    FR2422649A1|1979-11-09|
    SE454990B|1988-06-13|
    DK144779A|1979-10-11|
    DE2914494C2|1989-07-20|
    YU83079A|1983-12-31|
    CA1109067A|1981-09-15|
    HU187562B|1986-01-28|
    SE8404061D0|1984-08-10|
    JPH0312066B2|1991-02-19|
    IE48150B1|1984-10-17|
    YU40554B|1986-02-28|
    GB2018765B|1982-08-04|
    AU527748B2|1983-03-24|
    IE790753L|1979-10-10|
    SE445217B|1986-06-09|
    JPH0222276A|1990-01-25|
    GB2018765A|1979-10-24|
    JPH0233035B2|1990-07-25|
    FI66616B|1984-07-31|
    FI791125A|1979-10-11|
    NL191182C|1995-03-01|
    SE8404061L|1984-08-10|
    ZA791727B|1980-05-28|
    FI66616C|1984-11-12|
    DK156062C|1989-11-06|
    NL7902825A|1979-10-12|
    AU4588979A|1979-10-18|
    CH639079A5|1983-10-31|
    HU179424B|1982-10-28|
    FR2422649B1|1983-07-29|
    BE875475A|1979-10-10|
    JPS54135794A|1979-10-22|
    DE2914494A1|1979-10-18|
    GR72937B|1984-01-13|
    US4146718A|1979-03-27|
    NL191182B|1994-10-03|
    SE7903198L|1979-10-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    BE794964A|1972-02-04|1973-08-02|Bristol Myers Co|NEW HYPOTENSING AGENTS AND METHOD FOR PREPARING THEM|
    US3932407A|1973-11-19|1976-01-13|Bristol-Myers Company|Optionally substituted 1,2,3,5-tetrahydroimidezo-quinazolin-2-ones and 6-1,2,3,4-tetrahydropyimidoquinazolin-2-ones|
    US3988340A|1975-01-23|1976-10-26|Bristol-Myers Company|6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones|
    NL7807507A|1977-07-25|1979-01-29|Hoffmann La Roche|TRICYCLICAL CONNECTIONS.|CA1131631A|1979-06-20|1982-09-14|Madhukar S. Chodnekar|Quinazoline derivatives and pharmaceuticalpreparations|
    US4818273A|1983-11-14|1989-04-04|The Dow Chemical Company|Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides|
    US4837239A|1985-08-23|1989-06-06|SyntexInc.|Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins|
    US4761416A|1986-07-25|1988-08-02|SyntexInc.|N-N-disubstituted-ω-[2-amino-3--3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds|
    US4739056A|1986-11-26|1988-04-19|SyntexInc.|N-N-disubstituted-omega--3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds|
    JPH05271200A|1991-05-22|1993-10-19|Egyt Gyogyszervegyeszeti Gyar|Production of 6,7-dichloro-1,5-dihydro-imidazoquinazolin-2-one|
    US5391737A|1991-05-22|1995-02-21|Egis Gyogyszergyar|Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one|
    US5776962A|1994-08-03|1998-07-07|Cell Pathways, Inc.|Lactone compounds for treating patient with precancerous lesions|
    US5696159A|1994-08-03|1997-12-09|Cell Pathways, Inc.|Lactone compounds for treating patients with precancerous lesions|
    US6060477A|1995-06-07|2000-05-09|Cell Pathways, Inc.|Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives|
    US6046216A|1995-06-07|2000-04-04|Cell Pathways, Inc.|Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives|
    US6232312B1|1995-06-07|2001-05-15|Cell Pathways, Inc.|Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides|
    US6200980B1|1995-06-07|2001-03-13|Cell Pathways, Inc.|Method of treating a patient having precancerous lesions with phenyl purinone derivatives|
    US5874440A|1995-06-07|1999-02-23|Cell Pathways, Inc.|Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives|
    US6262059B1|1995-06-07|2001-07-17|Cell Pathways, Inc.|Method of treating a patient having precancerous lesions with quinazoline derivatives|
    US6046206A|1995-06-07|2000-04-04|Cell Pathways, Inc.|Method of treating a patient having a precancerous lesions with amide quinazoline derivatives|
    CA2171073A1|1995-12-04|1997-06-05|Philip C. Lang|Process for the preparation of ethyl-n- glycine|
    CA2238283C|1997-05-30|2002-08-20|Cell Pathways, Inc.|Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions|
    US5858694A|1997-05-30|1999-01-12|Cell Pathways, Inc.|Method for identifying compounds for inhibition of cancerous lesions|
    US5852035A|1997-12-12|1998-12-22|Cell Pathways, Inc.|Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazoloquinolin-4-amines|
    US6046199A|1998-01-14|2000-04-04|Cell Pathways, Inc.|Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives|
    US6410584B1|1998-01-14|2002-06-25|Cell Pathways, Inc.|Method for inhibiting neoplastic cells with indole derivatives|
    US5942520A|1998-01-27|1999-08-24|Cell Pathways, Inc.|Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazoloquinolone-4 amines|
    US5990117A|1998-04-15|1999-11-23|Cell Pathways, Inc.|Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives|
    US6180629B1|1998-08-14|2001-01-30|Cell Pathways, Inc.|[4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia|
    US6268372B1|1998-09-11|2001-07-31|Cell Pathways, Inc.|Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones|
    US6124303A|1998-09-11|2000-09-26|Cell Pathways, Inc.|Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2- purin-6-ones|
    US6200771B1|1998-10-15|2001-03-13|Cell Pathways, Inc.|Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia|
    US6187779B1|1998-11-20|2001-02-13|Cell Pathways, Inc.|Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives|
    US6369092B1|1998-11-23|2002-04-09|Cell Pathways, Inc.|Method for treating neoplasia by exposure to substituted benzimidazole derivatives|
    US6486155B1|1998-11-24|2002-11-26|Cell Pathways Inc|Method of inhibiting neoplastic cells with isoquinoline derivatives|
    US6034099A|1998-11-24|2000-03-07|Cell Pathways, Inc.|Method for inhibiting neoplastic lesions by administering 4-- 2, 3- dihydro-pyrazol-3-ones|
    US6077842A|1998-11-24|2000-06-20|Cell Pathways, Inc.|Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives|
    US6025394A|1999-01-29|2000-02-15|Cell Pathways, Inc.|Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols|
    US6020379A|1999-02-19|2000-02-01|Cell Pathways, Inc.|Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia|
    US6130053A|1999-08-03|2000-10-10|Cell Pathways, Inc.|Method for selecting compounds for inhibition of neoplastic lesions|
    EP1216037A2|1999-09-21|2002-06-26|Emory University|Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents|
    US6194420B1|1999-11-30|2001-02-27|Roberts Laboratories Inc.|2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof|
    US6555547B1|2000-02-28|2003-04-29|Cell Pathways, Inc.|Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative|
    US6569638B1|2000-03-03|2003-05-27|Cell Pathways, Inc|Method for screening compounds for the treatment of neoplasia|
    US6388073B1|2000-07-26|2002-05-14|Shire Us Inc.|Method for the manufacture of anagrelide|
    DE10301105B4|2003-01-09|2005-11-24|Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh|Use of 2-amino-2H-quinazoline derivatives for the treatment of myeloproliferative disorders, hypertension and bronchodilation|
    DE602004026405D1|2003-01-23|2010-05-20|Shire Holdings Ag|FORMULATION AND METHOD FOR THE TREATMENT OF THROMBOCYTHEMIA|
    AT412873B|2004-02-20|2005-08-25|Aop Orphan Pharmaceuticals Ag|Preparation of anagrelide hydrochloride, useful for thrombocyte suppression, using 2,3-dichlorobenzaldehyde as starting material, avoids use of toxic reagents|
    US20060030574A1|2004-08-04|2006-02-09|Shire Holdings Ag|Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors|
    US7700608B2|2004-08-04|2010-04-20|Shire Holdings Ag|Quinazoline derivatives and their use in the treatment of thrombocythemia|
    WO2007025177A2|2005-08-26|2007-03-01|Braincells, Inc.|Neurogenesis by muscarinic receptor modulation|
    EP2258357A3|2005-08-26|2011-04-06|Braincells, Inc.|Neurogenesis with acetylcholinesterase inhibitor|
    WO2007134136A2|2006-05-09|2007-11-22|Braincells, Inc.|Neurogenesis by modulating angiotensin|
    CA2625153A1|2005-10-21|2007-04-26|Braincells, Inc.|Modulation of neurogenesis by pde inhibition|
    EP1942879A1|2005-10-31|2008-07-16|Braincells, Inc.|Gaba receptor mediated modulation of neurogenesis|
    US20100216734A1|2006-03-08|2010-08-26|Braincells, Inc.|Modulation of neurogenesis by nootropic agents|
    WO2007104035A1|2006-03-08|2007-09-13|Braincells, Inc.|Modulation of neurogenesis by nootropic agents|
    US20100009983A1|2006-05-09|2010-01-14|Braincells, Inc.|5 ht receptor mediated neurogenesis|
    EP2026813A2|2006-05-09|2009-02-25|Braincells, Inc.|5 ht receptor mediated neurogenesis|
    US7998971B2|2006-09-08|2011-08-16|Braincells Inc.|Combinations containing a 4-acylaminopyridine derivative|
    US20100184806A1|2006-09-19|2010-07-22|Braincells, Inc.|Modulation of neurogenesis by ppar agents|
    CA2663347A1|2006-09-19|2008-03-27|Braincells, Inc.|Ppar mediated modulation of neurogenesis|
    GB0623749D0|2006-11-28|2007-01-10|Shire Llc|Substituted quinazolines|
    US7910597B2|2006-11-28|2011-03-22|Shire Llc|Substituted quinazolines|
    US8304420B2|2006-11-28|2012-11-06|Shire Llc|Substituted quinazolines for reducing platelet count|
    AR064106A1|2006-12-05|2009-03-11|Bayer Schering Pharma Ag|DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLINE USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISEASES ASSOCIATED WITH ANGIOGENESIS|
    EP2114856A1|2007-02-06|2009-11-11|Cipla Limited|Process for the preparation of ethyl-n- glycine hydrochloride|
    CN101463035A|2007-12-19|2009-06-24|华生制药私人有限公司|Improved method for producing anagrelide hydrochloride monohydrate|
    GB0808944D0|2008-05-16|2008-06-25|Shire Llc|Substituted quinazolines|
    GB0808953D0|2008-05-16|2008-06-25|Shire Llc|substituted quinazolines|
    GB0808968D0|2008-05-16|2008-06-25|Shire Llc|Substitute quinazolines|
    GB0808951D0|2008-05-16|2008-06-25|Shire Llc|Substituted quinazolines|
    GB0808947D0|2008-05-16|2008-06-25|Shire Llc|Substituted quinazolines|
    GB0808967D0|2008-05-16|2008-06-25|Shire Llc|Substitute quinazolines|
    GB2460915B|2008-06-16|2011-05-25|Biovascular Inc|Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor|
    US20100216805A1|2009-02-25|2010-08-26|Braincells, Inc.|Modulation of neurogenesis using d-cycloserine combinations|
    GB201004491D0|2010-03-18|2010-05-05|Shire Llc|Quinazoline analogues|
    GB201017783D0|2010-10-21|2010-12-01|Shire Llc|Process for the preparation of anagrelide and analogues thereof|
    US20150119399A1|2012-01-10|2015-04-30|President And Fellows Of Harvard College|Beta-cell replication promoting compounds and methods of their use|
    EP2945948B1|2013-01-18|2020-04-29|Synthon BV|Crystalline form ii of anagrelide hydrochloride monohydrate|
    WO2014139572A1|2013-03-14|2014-09-18|Synthon Bv|Process for making anagrelide|
    EP3013831A1|2013-06-28|2016-05-04|Synthon BV|Process for making anagrelide|
    CN106854162A|2016-12-13|2017-06-16|浙江海正化工股份有限公司|A kind of nitroaniline of 2,3 dichloro 6 and preparation method thereof|
    CN107903217B|2017-11-16|2021-11-23|湖北省宏源药业科技股份有限公司|Preparation method of anagrelide impurity B|
    JP2022501359A|2018-09-19|2022-01-06|モデルナティーエックス， インコーポレイテッド|PEG lipids and their use|
    CA3113353A1|2018-09-19|2020-03-26|Modernatx, Inc.|High-purity peg lipids and uses thereof|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/894,464|US4146718A|1978-04-10|1978-04-10|Alkyl 5,6-dichloro-3,4-dihydro-2-iminoquinazoline-3-acetate hydrohalides|
    [返回顶部]